ACF4 Antibody

What is AC4 Antibody and what biological target does it recognize?

AC4 antibodies are immunological reagents designed to detect and measure AC4 antigen in biological samples. The target is a reported synonym of the ADCY4 gene, which encodes adenylate cyclase 4, a protein that functions in G protein-coupled receptor (GPCR) signaling pathways and intracellular signal transduction. The human version of AC4 has a canonical amino acid length of 1077 residues and a protein mass of 119.8 kilodaltons, with two identified isoforms. AC4 belongs to the Adenylyl cyclase class-4/guanylyl cyclase protein family and plays critical roles in cellular signaling processes .

What cellular localization pattern does AC4 exhibit and in which tissues is it expressed?

AC4 protein is primarily localized in the cell membrane and cytoplasm. This dual localization reflects its function in transmembrane signaling processes. Expression analysis indicates that AC4 is widely distributed across many tissue types, making it a broadly relevant target for studies of GPCR-mediated signaling in different physiological contexts. This wide tissue distribution suggests that AC4 antibodies can be utilized in multiple research areas spanning cardiovascular, neurological, immunological and metabolic studies .

What are the validated research applications for AC4 antibodies?

AC4 antibodies have been validated for multiple experimental techniques in molecular and cellular biology. The primary applications include:

• Enzyme-Linked Immunosorbent Assay (ELISA) for quantitative analysis

• Flow Cytometry for cell-surface detection and sorting

• Western Blot for protein expression analysis and size determination

• Immunoprecipitation for protein complex isolation and characterization

• Immunohistochemistry for tissue localization studies

These diverse applications make AC4 antibodies versatile tools for both in vitro cellular studies and ex vivo tissue analyses .

How should researchers optimize Western blot protocols for AC4 detection?

For optimal Western blot detection of AC4, researchers should consider the protein's relatively large size (119.8 kDa) when selecting gel percentage and transfer conditions. A methodological approach includes:

• Sample preparation: Use RIPA buffer supplemented with protease inhibitors to prevent degradation

• Gel selection: 7.5-8% polyacrylamide gels are recommended for better resolution of high molecular weight proteins

• Transfer parameters: Employ wet transfer at lower voltage (30V) overnight at 4°C to ensure complete transfer

• Blocking: 5% non-fat dry milk in TBST for 1 hour at room temperature

• Primary antibody: Dilute AC4 antibodies to 1-5 μg/mL in blocking buffer and incubate overnight at 4°C

• Detection system: HRP-conjugated secondary antibodies followed by enhanced chemiluminescence

This approach maximizes sensitivity while minimizing background, particularly important for detecting endogenous levels of AC4 in cellular samples .

What controls should be included when using AC4 antibodies in immunological assays?

Rigorous experimental design for AC4 antibody applications should include the following controls:

• Positive control: Cell lines known to express AC4 (multiple tissue types express this protein)

• Negative control: Either knockout/knockdown cells or isotype-matched irrelevant antibodies

• Peptide competition assay: Pre-incubation of antibody with AC4-specific peptide should abolish signal

• Cross-reactivity assessment: Testing closely related family members (other adenylyl cyclases)

• Secondary-only control: To establish background signal levels

When using flow cytometry specifically, researchers should validate cells with and without CXCR4 transfection as demonstrated with similar engineered antibodies, where incubation with 1 μg/mL of fusion antibodies resulted in peak shifts of 67-74% for positive samples, while no shift was observed with non-transfected cells .

How can engineered AC4-related antibodies be utilized to modulate receptor signaling?

Engineered antibodies related to AC4 signaling pathways can serve as powerful tools for modulating receptor-mediated signaling cascades. A methodological framework includes:

• Target identification: Select specific receptors in the AC4 signaling pathway (e.g., GPCRs)

• Antibody engineering: Modify CDRs to target specific epitopes critical for signaling

• Functional validation: Test engineered antibodies using calcium flux assays

• Signaling assessment: Measure downstream effects on cAMP production via AC4

• Cellular response evaluation: Conduct migration or proliferation assays

Research on similar engineered antibodies like bAb-AC4 demonstrated effective blocking of calcium signaling post receptor activation. In chemotaxis assays, such antibodies inhibited ligand-dependent cell migration with EC50 values in the low nanomolar range (3.1 nM), completely neutralizing induced migration at 30 nM concentration compared to conventional antibodies that could not achieve complete inhibition even at saturating concentrations .

What strategies can enhance the specificity and affinity of AC4-targeting antibodies?

Improving AC4 antibody specificity and affinity can be achieved through several strategic approaches:

• CDR modification: CDR engineering, particularly in CDRH2 and CDRH3 regions

• Scaffold selection: Using appropriate antibody scaffolds like BLV1H12

• Directed evolution: Creating focused libraries with mutations in key CDRs

• Rational design: Grafting sequences that adopt β-hairpin conformations into CDRs

• Combinatorial approaches: Simultaneous modification of multiple CDRs

Studies with similar antibody engineering approaches have yielded significant improvements in binding affinity, with optimized variants achieving Kd values as low as 0.92 nM against their targets. CDRH2 modification offers particular advantages, including higher expression yields (17 mg/L) compared to CDRH3-modified variants, potentially due to reduced interference with heavy and light chain packing .

How can antibody-drug conjugates (ADCs) incorporating AC4-binding regions be optimized?

Development of effective antibody-drug conjugates utilizing AC4-binding regions requires optimization of several parameters:

• Drug-to-antibody ratio (DAR): Higher DARs generally increase potency, as demonstrated with similar ADCs where DAR4 variants exhibited 36-fold higher potency (EC50 = 25 ± 8 pM) compared to DAR2 variants (EC50 = 0.9 ± 0.4 nM)

• Linker chemistry: Selection between cleavable and non-cleavable linkers based on target cell characteristics

• Payload selection: Matching cytotoxic agents to target cell vulnerabilities

• Binding domain engineering: Optimizing affinity without compromising tissue penetration

• Stability assessment: Ensuring conjugate stability in circulation while maintaining release in target tissues

In vivo studies with similar ADC configurations demonstrated that high-DAR constructs significantly improved median survival in disease models (>100% increase) compared to control groups .

What methodologies are most effective for evaluating AC4 antibody-based therapeutic candidates?

Comprehensive evaluation of AC4 antibody-based therapeutics should follow this methodological framework:

• In vitro binding assessment:

  • Tag-lite homogeneous time-resolved fluorescence (HTRF) for affinity determination

  • Competition assays with natural ligands

  • Surface Plasmon Resonance (SPR) for kinetic analysis

• Functional characterization:

  • Calcium flux assays for signaling inhibition

  • Cyclic AMP accumulation tests to measure adenylyl cyclase activity

  • Receptor internalization studies using confocal microscopy

• Cellular activity evaluation:

  • Target cell cytotoxicity assays (for ADCs)

  • Migration/chemotaxis assays for functional antagonism

  • Cell-based reporter systems for pathway inhibition

• In vivo assessment:

  • Pharmacokinetic profiling

  • Biodistribution studies using fluorescently labeled antibodies

  • Efficacy in relevant disease models with survival analysis

This comprehensive testing cascade has proven effective in evaluating similar therapeutic antibodies, where functional antibodies developed through rational design demonstrated nanomolar potency in cellular assays and significant efficacy in animal models .

What are the optimal methods for determining AC4 antibody binding specificity and affinity?

Accurate determination of AC4 antibody binding characteristics requires complementary analytical approaches:

For determining binding constants (Kd), Tag-lite HTRF has proven particularly effective, allowing researchers to measure values as low as 0.92 nM for engineered antibodies against their targets .

How can researchers address common challenges in AC4 antibody applications?

Common challenges with AC4 antibodies can be addressed through systematic troubleshooting:

• Low signal issues:

  • Increase antibody concentration incrementally (1-10 μg/mL)

  • Optimize antigen retrieval methods for fixed samples

  • Extend primary antibody incubation time (overnight at 4°C)

  • Employ signal amplification systems (e.g., tyramide signal amplification)

• High background problems:

  • Increase blocking stringency (BSA + normal serum matching secondary antibody species)

  • Reduce secondary antibody concentration

  • Include detergents (0.1-0.3% Triton X-100) in washing buffers

  • Perform pre-adsorption of antibodies against non-specific proteins

• Cross-reactivity concerns:

  • Validate using knockout/knockdown controls

  • Perform peptide competition assays

  • Use multiple antibodies targeting different epitopes to confirm results

These approaches have been successfully applied to related antibody research, where careful optimization enabled researchers to detect specific binding in complex cellular environments with minimal non-specific interactions .

How might multi-CDR engineering expand the functional capabilities of AC4-targeting antibodies?

Emerging research suggests that simultaneous engineering of multiple CDRs could create bifunctional or multifunctional AC4-targeting antibodies with expanded capabilities:

• Dual targeting strategies:

  • Combining AC4 binding with recognition of downstream effectors

  • Simultaneous targeting of multiple epitopes on the same target

  • Engaging AC4 and related signaling components

• Implementation approaches:

  • CDRH2 and CDRH3 dual modification

  • Heavy and light chain CDR engineering

  • Incorporation of structurally distinct binding moieties

• Potential applications:

  • Bispecific antibodies that bridge AC4 with effector cells

  • Enhanced specificity through avidity effects

  • Simultaneous modulation of multiple signaling pathways

Research on similar antibody engineering platforms has demonstrated that "it may be possible to simultaneously graft two polypeptide agonists or antagonists into two distinct CDRs of a single antibody fusion protein," suggesting exciting possibilities for next-generation AC4-targeting therapeutics .

What novel analytical techniques are emerging for characterizing AC4 antibody interactions with signaling complexes?

Advanced analytical methods are expanding our ability to characterize complex interactions between AC4 antibodies and cellular signaling components:

• Emerging technologies:

  • Cryo-electron microscopy for structural analysis of antibody-target complexes

  • Single-molecule FRET for real-time interaction dynamics

  • CRISPR-based screening to identify critical interaction domains

  • Proximity labeling approaches (BioID, APEX) to map interaction networks

• Integration with systems biology:

  • Phosphoproteomics to map downstream effects on signaling cascades

  • Interactome analysis to identify novel AC4-associated proteins

  • Single-cell transcriptomics to characterize cellular responses to antibody treatment

• Computational approaches:

  • Molecular dynamics simulations of antibody-target interactions

  • Machine learning for predicting optimal antibody configurations

  • Network analysis to understand system-wide effects of AC4 modulation

These emerging approaches promise to provide unprecedented insights into how AC4 antibodies can be optimized to precisely modulate specific signaling pathways in complex biological systems, potentially leading to more targeted therapeutic applications with reduced off-target effects .